-
InflexionPoint Announces the Appointment of Pete Guzior as Chief Revenue Officer
Veteran manufacturing industry executive will lead the expansion of the company’s footprint and offerings, including AI and managed services RED BANK, N.J., April 17, 2026 /PRNewswire/ — InflexionPoint, a leading systems integrator partner to companies in regulated industries, is pleased to announce the appointment of Pete Guzior as chief revenue officer for the company.Guzior, who
-
Feromics Inc. Presents Functional Immunomics AI Platform at MIT AI Conference
Boston-based biotech powers AI with function-anchored data that reveals biological cause—not just correlation—across drug discovery, clinical development, and diagnostics. BOSTON, April 16, 2026 /PRNewswire/ — Feromics Inc., the first-of-its-kind functional immunomics platform built from the biology up, presented its Intelligent Design™ platform at the MIT AI Conference in Cambridge, Massachusetts on Tuesday. Co-Founder and CEO
-
Quintara Biosciences Introduces AmpValue: $4.99 Full-Length Nanopore Amplicon Sequencing
Optimized workflow ensures complete terminal coverage and overnight results for high-throughput screening. BOSTON, April 16, 2026 /PRNewswire/ — Quintara Biosciences today announced the launch of AmpValue, a new high-throughput nanopore-based amplicon sequencing service. AmpValue delivers full-length reads at a flat price of $4.99 per sample, coupled with guaranteed overnight turnaround to meet the rapid pace
-
Bold Therapeutics’ Clinical-Stage Anticancer Agent BOLD-100 Demonstrates Protective Effects Against Chemotherapy-Induced Peripheral Neuropathy
VANCOUVER, BC, April 16, 2026 /PRNewswire/ — Bold Therapeutics, a clinical-stage biopharmaceutical company that was founded to develop and commercialize novel metallotherapeutics, has shared new data highlighting the ability of its lead asset, BOLD-100, to demonstrate protective effects against chemotherapy-induced peripheral neuropathy. BOLD-100 is a first-in-class, ruthenium-based anticancer agent in Phase 2 clinical development for
-
Gallant Reports Positive Pilot Data for Feline Osteoarthritis Stem Cell Therapy; Receives FDA Eligibility for Expanded Conditional Approval Pathway
Randomized, placebo-controlled study shows over 76% of treated cats demonstrated improved quality of life SAN DIEGO, April 15, 2026 /PRNewswire/ — Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced positive results from a pilot clinical study evaluating intravenous (IV) uterine-derived mesenchymal stromal cell (UMSC) therapy in cats with
-
Priority Dispatch Corp. Launches Medical Transfer Protocol (MTP) SMART on FHIR App, Now Available in the Epic Showroom and on VectorCare’s Marketplace
Industry’s leading dispatch protocol system for interfacility transfers brings air and ground ambulance coordination directly into the Epic EHR SALT LAKE CITY, April 15, 2026 /PRNewswire/ — Priority Dispatch Corp., the global leader in emergency dispatch protocol systems, today announced the launch of its Medical Transfer Protocol (MTP) SMART on FHIR application, now available in
-
OmniActive’s Study Shows Capsimax Supports Natural GLP-1 Activity and Metabolism
New findings demonstrate benefits for exercise performance and intensity MUMBAI, India and BRIDGEWATER, N.J., April 15, 2026 /PRNewswire/ — OmniActive Health Technologies (OmniActive), a global leader in botanicals and science-backed natural ingredients, today announced new clinical research demonstrating that Capsimax, its branded Capsicum annuum extract delivering capsaicinoids, supports natural GLP-1 activity while improving exercise performance and
-
The Deerborne Group to Attend American Association for Cancer Research (AACR) Annual Meeting
SAN DIEGO, April 14, 2026 /PRNewswire/ — The Deerborne Group, a boutique consultancy focused exclusively on genomics and precision diagnostics, will attend the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22, 2026, in San Diego. Founded in 2020, The Deerborne Group advises Fortune 500 corporations, venture capital and private equity investors, and
-
As Tick Populations Rise, Tick BYTES and DIY Pest Control Launch Do-It-Yourself Initiative to Combat Lyme Disease
New partnership delivers affordable, eco-friendly solutions to help homeowners reduce tick exposure and disease risk WINDHAM, Maine, April 14, 2026 /PRNewswire/ — As deer tick populations expand across the United States and cases of Lyme disease and other tick-borne illnesses continue to rise, Tick BYTES LLC has released its 2026 Media Guide and announced a strategic
-
Meadow Biosciences Launches First National Telehealth Platform Dedicated To Leucovorin Care For Children With Autism
Physician-founded platform brings clinician-guided leucovorin access to families in all 50 states as autism rates reach historic highs and medication waitlists stretch to two years NEW YORK, April 14, 2026 /PRNewswire/ — Today, Meadow Biosciences launches a physician-led telehealth platform in all 50 states designed to help families of children with autism evaluate and access
